WT1 and acute myeloid leukemia: In this study, we evaluated the antitumor efficacy of aAVC-WT1 in an aggressively growing mouse leukemia model and a first-in-human trial for elderly patients with RR-AML, who are known to have poor prognosis compared with younger counterparts.33